Type 2 diabetes is not an event. It is the end of a long, silent process that typically takes a decade to complete, during which the standard annual blood panel reports nothing of concern.

This article is about that decade.

The central problem is that fasting glucose, the marker most often used to track blood sugar, is the last thing to become abnormal in the trajectory toward insulin resistance and type 2 diabetes. It stays normal because the body is working hard to keep it normal: the pancreas compensates for declining cellular sensitivity by producing more insulin, and it can sustain this compensation for years before anything visible appears on a lab report. The signal that is rising during this period, fasting insulin, is almost never included on a standard panel.

In 2019, researchers analyzed data from over 8,700 American adults across seven years and applied five criteria for optimal metabolic health: blood pressure, fasting glucose, HDL cholesterol, triglycerides, and waist circumference. The share of adults who met all five simultaneously was 12 percent.^[1]

This article covers the mechanism behind that number and the five markers that make a decade of silent dysfunction visible: fasting glucose, fasting insulin, HOMA-IR, HbA1c, and uric acid.

The normal system

Before examining how insulin resistance develops, it helps to understand exactly what insulin does and what happens when cells respond to it correctly.

Insulin is a peptide hormone produced by beta cells in the islets of Langerhans, clusters of endocrine cells scattered through the pancreas. After a meal, glucose enters the bloodstream from the gut. Rising blood glucose triggers the beta cells to release insulin into circulation. Insulin then travels to cells throughout the body, particularly in skeletal muscle, liver, and adipose tissue, and binds to insulin receptors on the cell surface.

The binding triggers a cascade. The insulin receptor is a tyrosine kinase: when insulin docks, the receptor phosphorylates itself and then activates a protein called insulin receptor substrate 1, or IRS-1. Phosphorylated IRS-1 activates phosphoinositide 3-kinase, PI3K, which in turn activates a signaling protein called Akt. Among Akt’s many downstream effects, it triggers the movement of glucose transporter 4, GLUT4, vesicles from their intracellular storage locations to the cell membrane. GLUT4 is the channel through which glucose enters the cell. Without the insulin signal completing this chain, that channel largely stays closed.

In a healthy fasting state, insulin is low, GLUT4 remains mostly intracellular, and cells rely primarily on fatty acids for fuel. After a meal, insulin rises, GLUT4 moves to the membrane, and glucose flows in. Within minutes of insulin binding, cellular glucose uptake increases substantially. Within a couple of hours, blood glucose returns to baseline, insulin falls, and the cycle resets.

This is the system that stops working in insulin resistance. Not all at once, and not obviously. The breakdown is gradual, and the body has substantial capacity to conceal it.

How resistance builds

The most well-characterized mechanism for insulin resistance begins with fat.

Adipose tissue is the body’s primary storage depot for excess energy, and under normal conditions it expands to accommodate increased caloric intake. But adipose tissue has a capacity limit, and when that limit is approached, the overflow has consequences. Excess fat begins accumulating in non-adipose tissues, a process called ectopic lipid deposition. The two most consequential sites are skeletal muscle and the liver.

In skeletal muscle, intramyocellular lipid accumulation generates a molecule called diacylglycerol, or DAG. Elevated intracellular DAG activates a specific isoform of protein kinase C, PKC-theta, which then phosphorylates IRS-1, but at a serine residue rather than the tyrosine residue required for normal signaling. Serine-phosphorylated IRS-1 cannot activate PI3K. The insulin receptor fires, the signal starts, and then stalls. GLUT4 does not move to the membrane. Glucose does not enter the cell.^[2]

The glucose that failed to enter muscle cells remains in the bloodstream. The pancreas detects the elevated concentration and responds the way it is designed to: by releasing more insulin. This additional insulin partially overcomes the impaired signaling, pushing enough glucose into cells to keep blood levels from rising too high. From the outside, fasting glucose looks normal. The body has compensated.

The liver develops resistance through a related but distinct mechanism. In the liver, excess lipid accumulation impairs insulin’s ability to suppress hepatic glucose production. A normal liver receiving the insulin signal stops producing glucose after a meal. An insulin-resistant liver continues producing glucose anyway, a condition called impaired hepatic insulin suppression. This eventually contributes to elevated fasting glucose, but early in the process the pancreas compensates for this as well by pushing insulin higher still.

What is visible at this stage: rising insulin. What is being measured on most standard panels: only glucose.

The decade the standard panel misses

The compensation mechanism is more robust than most people realize. The pancreas can sustain hyperinsulinemia, a state of chronically elevated insulin, for years before glucose regulation begins to break down. During that entire period, a standard annual blood panel measuring fasting glucose will report a normal result.

A 2009 prospective study followed 6,538 participants in the Whitehall II cohort from the late 1980s until they either developed type 2 diabetes or reached the end of follow-up. Looking backwards from the point of diagnosis, the researchers found that HOMA-IR, a calculated measure of insulin resistance, was elevated more than ten years before diagnosis. Fasting glucose did not start rising meaningfully until two to three years before the clinical threshold was crossed. Insulin resistance had been present and measurable for a decade before the standard glucose test became abnormal.^[3]

This is the structural problem with the standard panel. Fasting glucose is the defended quantity: the body’s compensatory mechanisms exist precisely to keep it in the normal range. The rising quantity, the one that actually reveals what is happening, is fasting insulin. And fasting insulin is almost never included on a routine annual panel.

HOMA-IR, the Homeostatic Model Assessment of Insulin Resistance, was first described by Matthews and colleagues in 1985. The formula takes fasting plasma glucose in mg/dL, multiplies it by fasting plasma insulin in µIU/mL, and divides by 405. The result is a dimensionless estimate of the degree of insulin resistance present.^[4] It is a derived value, not a separate test to order. But it requires both inputs, and one of those inputs, fasting insulin, is almost universally absent from standard panels.

The clinical thresholds worth knowing: a HOMA-IR below 1.0 reflects optimal insulin sensitivity. Values between 1.0 and 1.9 represent early impairment that is clinically significant even if not flagged. Above 2.75, most research definitions classify the result as insulin resistance. The standard lab threshold, when labs report it at all, is typically around 2.0 to 2.5. That catches only the more advanced cases.

A person can have a HOMA-IR of 2.6, indicating established insulin resistance, with a fasting glucose of 88 mg/dL that any clinician would call excellent. The glucose is fine because the insulin required to keep it fine is running at double its optimal level. Without fasting insulin, that entire picture is invisible.

Uric acid: the marker that works both ways

Uric acid enters the metabolic story at a point that most clinical discussions treat as a separate problem: gout. But uric acid’s role in metabolic dysfunction begins well before it crystallizes anywhere, and it involves a mechanism that makes it more than a passive downstream marker: uric acid actively worsens insulin resistance through a specific biochemical pathway.

The connection starts with fructose. When fructose is metabolized in the liver, it bypasses the regulatory step that governs glucose metabolism. Glucose phosphorylation by hexokinase is subject to product inhibition: when glucose-6-phosphate accumulates, the enzyme slows. Fructose follows a different route. It is phosphorylated to fructose-1-phosphate by fructokinase, which has no equivalent feedback inhibition. Fructose metabolism proceeds rapidly and without braking, depleting intracellular ATP and generating AMP as a byproduct. AMP is then converted, through a short enzymatic cascade involving AMP deaminase and xanthine oxidase, to uric acid.^[5]

The polyol pathway adds a second route, relevant in conditions of chronically elevated blood glucose. Glucose is converted to sorbitol by aldose reductase, then to fructose by sorbitol dehydrogenase. That fructose enters the same pathway and generates more uric acid. As blood glucose rises during compensated insulin resistance, the polyol pathway becomes more active, creating endogenous fructose and compounding uric acid production.

The downstream effect that closes the feedback loop involves nitric oxide. Uric acid inhibits endothelial nitric oxide synthase, the enzyme that produces nitric oxide in vessel walls. Nitric oxide is required for insulin-stimulated vasodilation: when insulin acts on endothelial cells, it triggers the relaxation of surrounding smooth muscle, increasing blood flow to skeletal muscle. Post-meal glucose uptake by muscle depends substantially on this vasodilation. When uric acid suppresses nitric oxide synthesis, the vasodilation fails, blood flow to muscle is impaired, and glucose clearance is reduced even when insulin levels are adequate.^[5]

The loop closes here. Metabolic dysfunction raises uric acid. Elevated uric acid suppresses nitric oxide and impairs insulin-stimulated glucose clearance. Impaired clearance worsens the metabolic environment that raises uric acid further.

The lab reference range for uric acid is calibrated to the gout threshold: around 7.0 mg/dL for men and 6.0 mg/dL for women. Gout is the symptomatic end of the spectrum. Metabolic consequences appear earlier. Evidence from large cohort studies finds that uric acid above 5.5 mg/dL is associated with increased metabolic syndrome risk independent of other established risk factors. A lab result of 6.5 mg/dL would be printed without comment. From a metabolic standpoint, it represents elevated uric acid with real downstream effects on insulin signaling, well below the threshold that prompts clinical concern.

When compensation fails

The pancreatic beta cells sustaining hyperinsulinemia through years of insulin resistance are under chronic stress. Sustained high-rate insulin secretion generates oxidative stress, endoplasmic reticulum stress, and eventually the accumulation of a misfolded protein aggregate called islet amyloid polypeptide, or IAPP. Over years, functional beta cell mass declines.

HbA1c, glycated hemoglobin, is the marker that catches the earliest evidence of this failure.

HbA1c reflects the proportion of hemoglobin molecules in red blood cells that have been non-enzymatically modified by glucose over time. Because red blood cells survive roughly 90 to 120 days, HbA1c integrates average blood glucose levels across that window. A single high fasting glucose reading does not substantially move HbA1c. Sustained elevation in mean glucose, even modestly, does.

This makes HbA1c sensitive to the earliest phase of compensation failure. When beta cell reserve begins to decline, the body can no longer keep average glucose levels as tightly controlled as before. Mean glucose rises slightly but persistently. A single fasting glucose measurement may still fall below 100 mg/dL. HbA1c, averaging over 90 days, registers the drift.

A 2004 analysis of over 4,000 men in the European Prospective Investigation into Cancer in Norfolk found that HbA1c predicted cardiovascular mortality continuously across the entire studied range, with risk increasing from 5.0 percent upward. There was no threshold below which the relationship flattened or disappeared. Risk rose incrementally through the 5.0 to 5.6 percent range that most labs and clinicians consider unremarkable.^[6]

The clinical pre-diabetes threshold of 5.7 percent is a risk stratification cutoff, not a metabolic safety boundary. It identifies people at substantially elevated risk of progressing to type 2 diabetes. It does not identify 5.6 percent as safe. For proactive monitoring purposes, values above 5.3 percent warrant attention even in the absence of any clinical label.

After HbA1c drifts, fasting glucose eventually rises as well. Pre-diabetes is defined at 100 to 125 mg/dL; type 2 diabetes at 126 mg/dL or above. These thresholds represent the point at which beta cell compensation has substantially broken down. They mark the end of a long silent phase, not the beginning of a problem.

Five markers and what optimal looks like

Each marker below covers three things: what it measures, why the lab reference range sets the bar too low, and what optimal looks like for proactive metabolic monitoring.

Fasting glucose

Fasting glucose measures the concentration of glucose in the blood after an overnight fast of at least eight hours. It is the marker the body most actively defends, which is why it is the last to become abnormal in compensated insulin resistance.

The lab flags results above 100 mg/dL as pre-diabetic. Optimal fasting glucose for metabolic health is 70 to 85 mg/dL. Values in the 86 to 99 range look acceptable on a report but can coexist with significant insulin resistance: glucose is in range because the pancreas is compensating, but the cost of that compensation, elevated insulin, is not being measured. Fasting glucose alone is not sufficient information.

Fasting insulin

Fasting insulin measures the concentration of insulin in the blood after an overnight fast. It is not included on standard panels. The lab reference range, when labs report it at all, typically extends to 20 or 25 µIU/mL, derived from the same population-distribution approach that makes all reference ranges misleading.

Fasting insulin above 10 µIU/mL indicates significant compensatory hyperinsulinemia. Optimal is below 5 µIU/mL. A value of 8 µIU/mL, unremarkable on most lab reports, may represent years of compensated insulin resistance in someone whose fasting glucose reads 88. This is the test that must be explicitly requested. Most labs can run it; most standard order forms do not include it.

HOMA-IR

HOMA-IR is calculated, not directly measured: fasting glucose in mg/dL multiplied by fasting insulin in µIU/mL, divided by 405. The result estimates insulin resistance from the relationship between the two fasting values.

Lab reports that include HOMA-IR typically flag results above 2.0 or 2.5 as elevated. Optimal is below 1.0. The range from 1.0 to 1.9 represents early metabolic impairment, clinically significant but not typically flagged. Above 2.75, most research definitions classify the result as insulin resistance.

The value of HOMA-IR over fasting glucose alone: a person with fasting glucose of 88 mg/dL and fasting insulin of 12 µIU/mL has a HOMA-IR of 2.6, indicating established insulin resistance despite a glucose reading that most clinicians would find unremarkable. Without fasting insulin, this is invisible.

HbA1c

HbA1c measures the percentage of hemoglobin that has been glycated over the preceding 90 days. It reflects sustained average glucose rather than a single time-point measurement, which makes it more stable and more informative about long-term glucose regulation than any single fasting reading.

The clinical pre-diabetes threshold is 5.7 percent. Type 2 diabetes is diagnosed at 6.5 percent. For proactive monitoring, an optimal target is below 5.3 percent. Values between 5.3 and 5.6 percent carry no diagnostic label but are associated with a continuous increase in cardiovascular risk in the epidemiological data. They deserve attention.

Uric acid

Uric acid is the end-product of purine metabolism. The lab reference range extends to 7.0 mg/dL for men and 6.0 mg/dL for women, calibrated to the gout threshold. Values below these thresholds are printed without comment.

For metabolic health, the relevant threshold is lower. Evidence linking elevated uric acid to metabolic syndrome, insulin resistance, and cardiovascular risk becomes apparent at values above 5.5 mg/dL. An optimal target is below 5.0 to 5.5 mg/dL. A result of 6.2 mg/dL would not generate a flag or a conversation. From a metabolic standpoint, it represents elevated uric acid with downstream effects on nitric oxide synthesis and insulin signaling.

What to order

A standard metabolic panel provides fasting glucose. That is the baseline. To it, add:

Fasting insulin. Must be requested explicitly. The test name varies by lab: look for “fasting insulin,” “insulin serum,” or “insulin, fasting.” It requires the same overnight fast as fasting glucose and is drawn at the same visit. Most labs can run it. Most standard order forms do not include it. If the ordering form does not have a line for it, it can be added as a free-text request.

HbA1c. May already be included on some comprehensive panels. If not, add it. HbA1c does not require fasting, though it is practical to draw at the same visit.

Uric acid. Rarely included in routine panels. Can be added to any comprehensive blood draw. No fasting required.

HOMA-IR. Not a separate test to order. Once fasting glucose and fasting insulin results are available, calculate it: fasting glucose in mg/dL, multiplied by fasting insulin in µIU/mL, divided by 405. The result tells you what the lab report does not.

The barrier is not cost or availability. These are basic, widely available tests. The barrier is that fasting insulin is not part of the standard ordering workflow, and most clinicians do not request it unless the patient asks. Asking is enough.

---

The standard annual blood panel is useful for detecting late-stage dysfunction. It is not useful for detecting the decade of compensated insulin resistance that precedes late-stage dysfunction.

The five markers in this article close most of that gap. The next article in this series covers cardiovascular risk: ApoB, Lp(a), triglycerides, hsCRP, and homocysteine. The cholesterol article covers the mechanism; the next article covers what to order and how to interpret it.

Previous: Normal Is Not the Same as Healthy

References

1. Araújo J, Cai J, Stevens J. (2019). Prevalence of optimal metabolic health in American adults: National Health and Nutrition Examination Survey 2009–2016. Metabolic Syndrome and Related Disorders, 17(1), 46–52. https://pubmed.ncbi.nlm.nih.gov/30507277/
2. Samuel VT, Shulman GI. (2012). Mechanisms for insulin resistance: common threads and missing links. Cell, 148(5), 852–871. https://pubmed.ncbi.nlm.nih.gov/22385956/
3. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet, 373(9682), 2215–2221. https://pubmed.ncbi.nlm.nih.gov/19515410/
4. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://pubmed.ncbi.nlm.nih.gov/3899825/
5. Johnson RJ, Segal MS, Sautin Y, et al. (2007). Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. American Journal of Clinical Nutrition, 86(4), 899–906. https://pubmed.ncbi.nlm.nih.gov/17921363/
6. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. (2004). Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Annals of Internal Medicine, 141(6), 413–420. https://pubmed.ncbi.nlm.nih.gov/15381514/